The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 development. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
80
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
30
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
450
bottom of page
Kommentare